Home LiteratureArticle Details
PMID: 21804596 Published · epublish English Journal Article Research Support, Non-U.S. Gov't Review

Cancer immunotherapy--revisited.

Nature reviews. Drug discovery ·Vol. 10 ·No. 8 ·2011-08-01 ·Pages 591-600

Lesterhuis WJ, Haanen JB, Punt CJ

Abstract

Our insight into antitumour immune responses has increased considerably during the past decades, yet the development of immunotherapy as a treatment modality for cancer has been hampered by several factors. These include difficulties in the selection of the optimal dose and schedule, the methods of evaluation, and financial support. Although durable clinical remissions have been observed with various immunotherapeutic strategies, the percentage of patients who benefited from these interventions has remained too small to justify the general use of such strategies. However, the recent positive results of clinical trials with novel immunoactive drugs as well as the unexpected finding of a positive interaction between immunotherapy and chemotherapy may herald a new era for the immunotherapy of cancer.

MeSH Terms
Antibodies, Monoclonal/therapeutic use Antigens, CD/immunology CTLA-4 Antigen Cancer Vaccines/immunology Clinical Trials as Topic Humans Immunotherapy/methods Immunotherapy, Adoptive Ipilimumab Neoplasms/immunology,therapy Research Design T-Lymphocytes, Regulatory/immunology
Chemicals
Antibodies, Monoclonal Antigens, CD CTLA-4 Antigen CTLA4 protein, human Cancer Vaccines Ipilimumab
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Lesterhuis W Joost
Department of Medical Oncology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500HB Nijmegen, The Netherlands.
Haanen John B A G
Punt Cornelis J A
References (111)
111 references, click to expand
  1. Dendritic cell vaccines in melanoma: from promise to proof?
    Crit Rev Oncol Hematol. 2008 May;66(2):118-34 PMID: 18262431
  2. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.
    Blood. 2005 Apr 1;105(7):2862-8 PMID: 15591121
  3. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.
    J Exp Med. 1976 May 1;143(5):1283-8 PMID: 1083422
  4. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.
    J Exp Med. 2002 May 20;195(10):1279-88 PMID: 12021308
  5. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.
    J Immunol. 2003 May 15;170(10):4905-13 PMID: 12734333
  6. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
    Blood. 2007 Nov 1;110(9):3192-201 PMID: 17616639
  7. CpG oligodeoxynucleotide enhances tumor response to radiation.
    Cancer Res. 2004 Aug 1;64(15):5074-7 PMID: 15289307
  8. A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.
    Br J Cancer. 2010 Oct 26;103(9):1415-21 PMID: 20924373
  9. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism.
    J Immunol. 2009 Jul 1;183(1):137-44 PMID: 19535620
  10. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.
    Blood. 2005 Sep 15;106(6):2018-25 PMID: 15914560
  11. Improved endpoints for cancer immunotherapy trials.
    J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97 PMID: 20826737
  12. Calreticulin exposure dictates the immunogenicity of cancer cell death.
    Nat Med. 2007 Jan;13(1):54-61 PMID: 17187072
  13. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.
    Eur Urol. 2010 May;57(5):766-73 PMID: 20034729
  14. Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects.
    Br J Cancer. 1983 Jan;47(1):123-33 PMID: 6600395
  15. In situ tumor ablation creates an antigen source for the generation of antitumor immunity.
    Cancer Res. 2004 Jun 1;64(11):4024-9 PMID: 15173017
  16. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
    Eur J Cancer. 2009 Jan;45(2):228-47 PMID: 19097774
  17. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
    Blood. 2010 Feb 4;115(5):925-35 PMID: 19880495
  18. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
    Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3515-9 PMID: 8170938
  19. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
    Science. 2002 Oct 25;298(5594):850-4 PMID: 12242449
  20. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
    J Clin Oncol. 2011 Jul 10;29(20):2787-94 PMID: 21632504
  21. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
    J Clin Oncol. 2005 Apr 1;23(10):2346-57 PMID: 15800326
  22. Inhibition of mutated, activated BRAF in metastatic melanoma.
    N Engl J Med. 2010 Aug 26;363(9):809-19 PMID: 20818844
  23. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
    Lancet. 2009 Jul 25;374(9686):301-14 PMID: 19586656
  24. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
    Nat Med. 1998 Mar;4(3):328-32 PMID: 9500607
  25. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
    J Clin Oncol. 2009 Jan 10;27(2):186-92 PMID: 19064967
  26. Cancer; a biological approach. I. The processes of control.
    Br Med J. 1957 Apr 6;1(5022):779-86 PMID: 13404306
  27. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
    Br J Cancer. 2009 Apr 7;100(7):1111-9 PMID: 19277038
  28. Cancer immunotherapy: moving beyond current vaccines.
    Nat Med. 2004 Sep;10(9):909-15 PMID: 15340416
  29. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
    N Engl J Med. 2007 May 10;356(19):1928-43 PMID: 17494926
  30. "MIATA"-minimal information about T cell assays.
    Immunity. 2009 Oct 16;31(4):527-8 PMID: 19833080
  31. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
    J Clin Oncol. 2011 Mar 1;29(7):917-24 PMID: 21282551
  32. Improved survival with ipilimumab in patients with metastatic melanoma.
    N Engl J Med. 2010 Aug 19;363(8):711-23 PMID: 20525992
  33. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.
    J Clin Oncol. 2006 Dec 1;24(34):5373-80 PMID: 17135638
  34. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    J Exp Med. 1999 Aug 2;190(3):355-66 PMID: 10430624
  35. Designing vaccines based on biology of human dendritic cell subsets.
    Immunity. 2010 Oct 29;33(4):464-78 PMID: 21029958
  36. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy.
    Nat Biotechnol. 2005 Nov;23(11):1407-13 PMID: 16258544
  37. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels.
    Cancer Res. 2010 Jun 15;70(12):4850-8 PMID: 20501849
  38. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
    J Clin Oncol. 2005 Dec 10;23(35):8968-77 PMID: 16204013
  39. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
    N Engl J Med. 2009 Nov 5;361(19):1838-47 PMID: 19890126
  40. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
    N Engl J Med. 1985 Dec 5;313(23):1485-92 PMID: 3903508
  41. Phase I/II study of ipilimumab for patients with metastatic melanoma.
    J Clin Oncol. 2008 Dec 20;26(36):5950-6 PMID: 19018089
  42. A Toll-like receptor recognizes bacterial DNA.
    Nature. 2000 Dec 7;408(6813):740-5 PMID: 11130078
  43. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
    N Engl J Med. 2011 Jun 2;364(22):2119-27 PMID: 21631324
  44. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.
    Nat Med. 2005 Nov;11(11):1238-43 PMID: 16227988
  45. Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide.
    Immunology. 1972 Oct;23(4):493-501 PMID: 4538884
  46. Treatment of vulvar intraepithelial neoplasia with topical imiquimod.
    N Engl J Med. 2008 Apr 3;358(14):1465-73 PMID: 18385498
  47. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.
    Cancer Immunol Immunother. 2007 Dec;56(12):1875-83 PMID: 17479266
  48. Regression of established tumors and induction of tumor immunity by intratumor chemotherapy.
    J Natl Cancer Inst. 1976 Apr;56(4):829-32 PMID: 176411
  49. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
    Ann Surg Oncol. 2010 Mar;17(3):718-30 PMID: 19915919
  50. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
    Cancer Res. 2003 Aug 1;63(15):4490-6 PMID: 12907622
  51. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
    Clin Cancer Res. 2010 Oct 15;16(20):5067-78 PMID: 20736326
  52. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy.
    Cancer J. 2010 Jul-Aug;16(4):399-403 PMID: 20693853
  53. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.
    Nat Med. 2009 Oct;15(10):1170-8 PMID: 19767732
  54. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
    Clin Cancer Res. 2002 Dec;8(12):3702-9 PMID: 12473579
  55. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
    J Clin Invest. 2005 Dec;115(12):3623-33 PMID: 16308572
  56. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers.
    Ann Intern Med. 1985 Jul;103(1):32-6 PMID: 4003987
  57. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
    Cancer Res. 2001 Sep 1;61(17):6451-8 PMID: 11522640
  58. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation.
    Blood. 2010 Jan 14;115(2):289-95 PMID: 19901260
  59. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
    Mol Ther. 2010 Apr;18(4):843-51 PMID: 20179677
  60. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.
    Int J Cancer. 2011 Jul 15;129(2):507-12 PMID: 20839259
  61. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells.
    Ann N Y Acad Sci. 2009 Sep;1174:99-106 PMID: 19769742
  62. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
    N Engl J Med. 2011 Jun 30;364(26):2507-16 PMID: 21639808
  63. Inhibitory B7-family molecules in the tumour microenvironment.
    Nat Rev Immunol. 2008 Jun;8(6):467-77 PMID: 18500231
  64. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
    Blood. 2009 Jul 16;114(3):535-46 PMID: 19451549
  65. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
    J Clin Oncol. 2010 Mar 1;28(7):1099-105 PMID: 20100959
  66. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis.
    Nature. 1974 Oct 11;251(5475):547-8 PMID: 4547543
  67. Toll-dependent selection of microbial antigens for presentation by dendritic cells.
    Nature. 2006 Apr 6;440(7085):808-12 PMID: 16489357
  68. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.
    Nature. 1974 Apr 19;248(5450):701-2 PMID: 4133807
  69. Immunogenic death of colon cancer cells treated with oxaliplatin.
    Oncogene. 2010 Jan 28;29(4):482-91 PMID: 19881547
  70. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro.
    Int J Cancer. 2003 Apr 20;104(4):437-45 PMID: 12584740
  71. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.
    J Clin Oncol. 2005 Aug 20;23(24):5779-87 PMID: 16110035
  72. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med. 2004 Sep;10(9):942-9 PMID: 15322536
  73. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
    Science. 1991 Dec 13;254(5038):1643-7 PMID: 1840703
  74. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.
    Clin Cancer Res. 2011 Feb 15;17(4):841-8 PMID: 21177412
  75. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
    Clin Cancer Res. 2009 Dec 1;15(23):7412-20 PMID: 19934295
  76. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
    Nat Med. 2007 Sep;13(9):1050-9 PMID: 17704786
  77. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
    J Clin Oncol. 1992 Jan;10(1):52-60 PMID: 1727926
  78. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
    Cancer Res. 2010 Apr 15;70(8):3052-61 PMID: 20388795
  79. Why do viruses cause cancer? Highlights of the first century of human tumour virology.
    Nat Rev Cancer. 2010 Dec;10(12):878-89 PMID: 21102637
  80. In vivo colocalization of antigen and CpG [corrected] within dendritic cells is associated with the efficacy of cancer immunotherapy.
    Cancer Res. 2008 Jul 1;68(13):5390-6 PMID: 18593941
  81. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
    N Engl J Med. 1987 Apr 9;316(15):889-97 PMID: 3493432
  82. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients.
    Int J Cancer. 2009 Jan 1;124(1):130-9 PMID: 18839429
  83. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.
    J Clin Invest. 2010 Apr;120(4):1111-24 PMID: 20234093
  84. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Clin Cancer Res. 2010 May 1;16(9):2646-55 PMID: 20406835
  85. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
    Ann Oncol. 2006 Apr;17(4):563-70 PMID: 16418308
  86. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults.
    Cell. 1996 Sep 20;86(6):973-83 PMID: 8808632
  87. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.
    Lancet. 1999 Jan 2;353(9146):14-7 PMID: 10023944
  88. Ipilimumab: controversies in its development, utility and autoimmune adverse events.
    Cancer Immunol Immunother. 2009 May;58(5):823-30 PMID: 19198837
  89. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.
    N Engl J Med. 1987 Apr 9;316(15):898-905 PMID: 3493433
  90. Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.
    Cancer Immunol Immunother. 2011 Jan;60(1):75-85 PMID: 20857100
  91. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.
    J Exp Med. 2005 Jan 17;201(2):249-57 PMID: 15657294
  92. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
    N Engl J Med. 2011 Jun 30;364(26):2517-26 PMID: 21639810
  93. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
    J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 PMID: 10655437
  94. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
    Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):644-53 PMID: 17255288
  95. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
    J Exp Med. 2009 Aug 3;206(8):1717-25 PMID: 19581407
  96. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    N Engl J Med. 2010 Jul 29;363(5):411-22 PMID: 20818862
  97. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.
    J Immunol. 1995 Aug 1;155(3):1151-64 PMID: 7636184
  98. Cancer regression in patients after transfer of genetically engineered lymphocytes.
    Science. 2006 Oct 6;314(5796):126-9 PMID: 16946036
  99. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
    Cancer Res. 2006 Apr 1;66(7):3381-5 PMID: 16585157
  100. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity.
    Nature. 1997 Jul 24;388(6640):394-7 PMID: 9237759
  101. Immunotherapy of distant metastatic disease.
    Ann Oncol. 2009 Aug;20 Suppl 6:vi41-50 PMID: 19617297
  102. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
    Blood. 2010 Nov 18;116(20):4099-102 PMID: 20668228
  103. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
    J Urol. 1976 Aug;116(2):180-3 PMID: 820877
  104. Immune therapy for cancer.
    Annu Rev Immunol. 2009;27:83-117 PMID: 19007331
  105. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
    Lancet. 2005 Oct 1;366(9492):1189-96 PMID: 16198768
  106. Landmark approval for Dendreon's cancer vaccine.
    Nat Biotechnol. 2010 Jun;28(6):531-2 PMID: 20531312
  107. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution.
    J Exp Med. 1973 May 1;137(5):1142-62 PMID: 4573839
  108. The biological treatment of renal-cell carcinoma and melanoma.
    Lancet Oncol. 2002 Feb;3(2):89-96 PMID: 11902528
  109. The anticancer immune response: indispensable for therapeutic success?
    J Clin Invest. 2008 Jun;118(6):1991-2001 PMID: 18523649
  110. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy.
    N Engl J Med. 1957 Sep 12;257(11):491-6 PMID: 13464965
  111. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.
    Cancer Cell. 2010 Nov 16;18(5):485-98 PMID: 21035406
Article Info
Journal
Nature reviews. Drug discovery
Abbr.
Nat Rev Drug Discov
ISSN
1474-1784
DOI
10.1038/nrd3500
Published
2011-08-01
Epub
2011-00-01
Pages
591-600
Language
English
Region
England
NLM ID
101124171
Subset
IM
External Links
PubMed source DOI: 10.1038/nrd3500 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2